1. Home
  2. JFIN vs TLSA Comparison

JFIN vs TLSA Comparison

Compare JFIN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$2.21

Market Cap

149.7M

Sector

Finance

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.93

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
TLSA
Founded
2011
2013
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.7M
155.3M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
JFIN
TLSA
Price
$2.21
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
69.7K
256.6K
Earning Date
06-03-2026
05-04-2026
Dividend Yield
17.47%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.19
$0.91
52 Week High
$15.03
$2.60

Technical Indicators

Market Signals
Indicator
JFIN
TLSA
Relative Strength Index (RSI) 19.99 33.91
Support Level N/A N/A
Resistance Level $4.54 $1.48
Average True Range (ATR) 0.18 0.12
MACD -0.02 -0.03
Stochastic Oscillator 1.03 5.17

Price Performance

Historical Comparison
JFIN
TLSA

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: